Amgen (NASDAQ:AMGN) Stock Gets Price Target Boost from Leerink Partners

Amgen (NASDAQ:AMGN) had its price target increased by research analysts at Leerink Partners from $395.00 to $464.00 in a research report issued on Thursday, Benzinga reports. The firm presently has a “market perform” rating on the medical research company’s stock. Leerink Partners‘s price objective suggests a potential upside of 0.81% from the stock’s previous close.

Several other analysts have also commented on the stock. JPMorgan Chase & Co. increased their target price on shares of Amgen from $350.00 to $425.00 and gave the company a “neutral” rating in a research note on Wednesday. Canaccord Genuity Group raised their target price on shares of Amgen from $384.00 to $440.00 and gave the stock a “hold” rating in a report on Wednesday. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, October 18th. Mizuho lifted their price target on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 18th. Finally, Royal Bank Of Canada upped their price target on Amgen from $430.00 to $470.00 and gave the company an “outperform” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, seventeen have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $419.10.

Amgen Price Performance

Amgen stock traded down $18.20 during midday trading on Thursday, hitting $460.28. The company’s stock had a trading volume of 4,018,726 shares, compared to its average volume of 2,758,203. Amgen has a 12 month low of $312.39 and a 12 month high of $483.99. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The company has a market capitalization of $248.84 billion, a PE ratio of 26.70, a price-to-earnings-growth ratio of 3.38 and a beta of 0.43. The stock’s 50-day moving average price is $421.56 and its 200-day moving average price is $376.90.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating the consensus estimate of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 128.15%. The company had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. During the same quarter last year, the firm posted $5.64 EPS. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. Analysts anticipate that Amgen will post 22.96 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On Amgen

A number of large investors have recently made changes to their positions in AMGN. State Street Corp grew its holdings in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after buying an additional 11,656,755 shares in the last quarter. MW Advisory LLC acquired a new position in Amgen during the second quarter valued at $1,054,000. Baird Financial Group Inc. raised its position in Amgen by 1.6% during the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock valued at $123,057,000 after buying an additional 5,496 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in Amgen by 105.8% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 13,514 shares of the medical research company’s stock worth $5,696,000 after acquiring an additional 6,947 shares in the last quarter. Finally, Nilsine Partners LLC purchased a new stake in Amgen in the 2nd quarter worth about $3,329,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: A real-world study of more than 500,000 people with heart disease found Repatha was associated with a 20% lower risk of fatal or nonfatal heart attacks than ezetimibe. The findings could strengthen the drug’s case in non-statin treatment decisions. Repatha study
• Positive Sentiment: Amgen reported Q3 revenue of $10.37 billion, up 8.5% year over year, and adjusted EPS of $6.45, beating estimates. It also raised its 2026 outlook, supported by growth products including Repatha and Imdelltra. Q3 results
• Neutral Sentiment: The company announced a collaboration with the National Organization for Rare Disorders to help speed diagnosis of selected rare autoimmune diseases, while also highlighting AI-assisted RNA drug discovery. These initiatives may support longer-term pipeline growth, but are not near-term revenue drivers. Rare disease and RNA initiatives
• Negative Sentiment: Guggenheim raised its price target to $435 but kept a neutral rating, putting its estimate below the current share level. The stock’s retreat may also reflect concerns that biosimilar competition is pressuring Prolia and Xgeva, despite growth elsewhere in the portfolio. Biosimilar pressure and earnings context

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.